Evidence map›Paper›PMID 38757942›Full record

ReviewThe Journal of general virology2024

Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus.

HBV2023, Lena Allweiss, Chari Cohen, Joao Dias, Valeria Fumagalli, Haitao Guo, James M Harris, Jianming Hu, Matteo Iannacone, Masanori Isogawa and 21 more

Abstract readReview
In one paragraph

Review in The Journal of general virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

HBV2023Various- see supplementary material.
Lena AllweissDepartment of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Chari CohenHepatitis B Foundation, Doylestown, PA, USA.
Joao DiasLaboratoire de Virologie Moléculaire, CNRS Université de Montpellier, Montpellier, France.
Valeria FumagalliDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Haitao GuoDepartment of Microbiology and Molecular Genetics; Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
James M HarrisNuffield Department of Medicine, University of Oxford, Oxford, UK.
Jianming HuDepartment of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Matteo IannaconeDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Masanori IsogawaDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Wen-Juei JengDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan, Taiwan, ROC.
Kyun-Hwan KimDepartment of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Republic of Korea.
Anna KramvisAnna Kramvis Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Wenhui LiNational Institute of Biological Sciences, Beijing, PR China.
Julie LuciforaCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Masamichi MuramatsuDepartment of Infectious Disease Research, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Hyogo, Japan.
Christine NeuveutLaboratoire de Virologie Moléculaire, CNRS Université de Montpellier, Montpellier, France.
Alexander PlossDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Teresa PollicinoDepartment of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy.
Ulrike ProtzerInstitute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.
Anthony TanEmerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
Yasuhito TanakaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Thomas TuStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney at Westmead Hospital, Westmead, NSW, Australia.
Senko TsukudaNuffield Department of Medicine, University of Oxford, Oxford, UK.
Robert ThimmeDepartment of Medicine II, University Hospital Freiburg, Breisgau, Germany.
Stephan UrbanGerman Center for Infection Research (DZIF), Braunschweig, Germany.
Koichi WatashiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
Zhenghong YuanKey Lab of Medical Molecular Virology, Shanghai Medical College, Fudan University, Shanghai, PR China.
Shiou-Hwei YehGraduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan, ROC.
Jane A McKeatingChinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Peter A RevillVictorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shuchang Silvia Liu · 2019 to 2026
$10.9M
Rational design and efficacy testing of vaccines against HCVR01AI168048 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Alexander Andrianov, Thomas R Fuerst · 2022 to 2026
$7.1M
Genetic Viral and Host Adaptations to Breach Species Barriers of HCVR01AI107301 · NIAID · PRINCETON UNIVERSITY · PI Thomas Pietschmann, Alexander Ploss · 2013 to 2026
$6.0M
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infectionR01AI138797 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PLOSS, ALEXANDER, SU, LISHAN · 2018 to 2022
$3.9M
Mechanisms of Hepadnavirus Assembly and ReplicationR37AI043453 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Jianming Hu · 2018 to 2026
$3.8M
Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment ResponseR01AI146917 · NIAID · LOYOLA UNIVERSITY CHICAGO · PI DAHARI, HAREL · 2020 to 2024
$3.5M
Molecular Mechanisms of HBV cccDNA FormationR01AI110762 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2016 to 2025
$3.5M
Mechanisms of hepatitis B virus cccDNA formationR01AI153236 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER · 2020 to 2024
$2.8M
The Role of HBeAg in HBV PersistenceR01AI134818 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Haitao Guo · 2018 to 2026
$2.7M
Epigenetic Regulation of HBV cccDNA TranscriptionR01AI150255 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2020 to 2024
$2.0M
HBV cccDNA and integrated DNA in HIV coinfection and HBV monoinfectionR56AI179574 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GUO, HAITAO, LAU, DARYL T · 2023 to 2023
$847k
NCI NIH HHS P30 CA047904NIAID NIH HHS R01 AI107301NIAID NIH HHS R01 AI110762NIAID NIH HHS R01 AI134818NIAID NIH HHS R01 AI138797NIAID NIH HHS R01 AI146917NIAID NIH HHS R01 AI150255NIAID NIH HHS R01 AI153236NIAID NIH HHS R01 AI168048NIAID NIH HHS R21 AI179929NIAID NIH HHS R37 AI043453NIAID NIH HHS R56 AI179574NIDDK NIH HHS P30 DK120531Wellcome Trust 200838/Z/16/Z
6 · The paper itself

Abstract

Since its discovery in 1965, our understanding of the hepatitis B virus (HBV) replication cycle and host immune responses has increased markedly. In contrast, our knowledge of the molecular biology of hepatitis delta virus (HDV), which is associated with more severe liver disease, is less well understood. Despite the progress made, critical gaps remain in our knowledge of HBV and HDV replication and the mechanisms underlying viral persistence and evasion of host immunity. The International HBV Meeting is the leading annual scientific meeting for presenting the latest advances in HBV and HDV molecular virology, immunology, and epidemiology. In 2023, the annual scientific meeting was held in Kobe, Japan and this review summarises some of the advances presented at the Meeting and lists gaps in our knowledge that may facilitate the development of new therapies.

Indexed as

Hepatitis BHepatitis B virusHepatitis Delta VirusVirus ReplicationHepatitis DHost-Pathogen InteractionsHumansJapanMolecular BiologyInternational HBV Meeting 2023

Identifiers

PMID38757942
PMCPMC11258880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.